Evidence map›Paper›PMID 37873239›Full record

ArticlebioRxiv : the preprint server for biology2023

The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics.

David J Sherman, Lei Liu, Jennifer L Mamrosh, Jiansong Xie, John Ferbas, Brett Lomenick, Mark S Ladinsky, Rati Verma, Ingrid C Rulifson, Raymond J Deshaies

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 8 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

David J ShermanAmgen Research, Thousand Oaks, CA 91320, USA.
Lei LiuAmgen Research, South San Francisco, CA 94080, USA.
Jennifer L MamroshAmgen Research, Thousand Oaks, CA 91320, USA.
Jiansong XieAmgen Research, Thousand Oaks, CA 91320, USA.
John FerbasAmgen Research, Thousand Oaks, CA 91320, USA.
Brett LomenickProteome Exploration Laboratory, California Institute of Technology, Pasadena, CA 91125, USA.
Mark S LadinskyDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Rati VermaAmgen Research, Thousand Oaks, CA 91320, USA.
Ingrid C RulifsonAmgen Research, South San Francisco, CA 94080, USA.
Raymond J DeshaiesAmgen Research, Thousand Oaks, CA 91320, USA.
Amgen (United States) · USCalifornia Institute of Technology · US

Funding

Virus TransmissionP50AI150464 · NIAID · UNIVERSITY OF UTAH · PI HOPE, THOMAS · 2019 to 2021
$14.9M
Purchase of a nanoLC-QTRAP Mass Spectrometer for Targeted Proteomics StudiesS10OD010788 · OD · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI HESS, SONJA · 2013 to 2013
$600k
Acquisition of a Q-Exactive Plus mass spectrometer.S10OD020013 · OD · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI HESS, SONJA · 2015 to 2015
$600k
NIAID NIH HHS P50 AI150464NIH HHS S10 OD010788NIH HHS S10 OD020013
6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD), is a progressive metabolic disorder that begins with aberrant triglyceride accumulation in the liver and can lead to cirrhosis and cancer. A common variant in the gene

Identifiers

PMID37873239
PMCPMC10592801
OpenAlexW4387638249

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.